Home » Articles posted by DR ANTHONY MELVIN CRASTO Ph.D (Page 404)
Author Archives: DR ANTHONY MELVIN CRASTO Ph.D
Celgene: Apremilast For Psoriatic Arthritis successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.
Celgene data from its ongoing Phase III trial of apremilast this month showing the drug successfully reduced psoriatic arthritis symptoms by at least 20% versus placebo.
The data is good news for the 1 million diagnosed patients in the U.S. and Europe and for shareholders eager to see apremilast win market share in the multibillion dollar immunology market.
read all at
Scientists reveal drinking champagne could improve memory
![]()
(Medical Xpress)—New research shows that drinking one to three glasses of champagne a week may counteract the memory loss associated with ageing, and could help delay the onset of degenerative brain disorders, such as dementia.
Read more at:
http://medicalxpress.com/news/2013-05-scientists-reveal-champagne-memory.html
Glenmark Generics receives final ANDA approvals for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg
May 15, 2013: Glenmark Generics Inc., USA a subsidiary of Glenmark Generics Limited has been granted final abbreviated new drug approvals (ANDA’s) from the United States Food and Drug
Administration (US FDA) for Zolmitriptan Tablets, 2.5 and 5mg and Zolmitriptan Orally Disintegrating Tablets, 2.5 and 5mg. Glenmark will commence distribution of the product immediately.
Zolmitriptan Tablets and Zolmitriptan ODT are Glenmark’s generic versions of Zomig® and Zomig ZMT® by AstraZeneca, indicated for the acute treatment of migraine headaches in adults.
According to IMS Health for the 12 month period ending December 2012, the products garnered annual sales of USD 176 million.
UK researchers have developed an injectable microgel that can completely restore the mechanical function of damaged spinal discs – at least in an animal model.

Back problems could be tackled with an injectable microgel
read all at
http://www.rsc.org/chemistryworld/2012/08/new-gel-repairs-damaged-discs
Experimental Drug Seems to Aid Memory in Mice With Alzheimer’s

TUESDAY May 14, 2013 — An experimental drug improved the memory and brain function in older mice with advanced symptoms of Alzheimer’s disease, according to a new study.
read this at
http://www.drugs.com/news/experimental-seems-aid-memory-mice-alzheimer-s-44538.html
Quizartinib — a Phase 2B trial treatment for acute myeloid leukemia
![]()
quizartinib
Ambit Biosciences
Ambit Biosciences (NASDAQ:AMBI) is a biotech company that focuses on treatments that inhibit kinases, which are drivers for diseases such as cancer. Three drugs are in development, with the lead one being quizartinib — a Phase 2B trial treatment for acute myeloid leukemia.
However, AMBI’s collaboration agreement with Astellas Pharma (OTC:ALPMY) is set to expire in September, and if it is not replaced, it could mean a delay in Phase 3 trials for quizartinib. Keep in mind that AMBI generated $23.8 million in collaboration revenues last year.
Quizartinib (AC220) is a small molecule receptor tyrosine kinase inhibitor that is currently under development for the treatment of acute myeloid leukaemia. Its molecular target isFLT3, also known as CD135 which is a proto-oncogene.[1]
Flt3 mutations are among the most common mutations in acute myeloid leukaemia due tointernal tandem duplication of Flt3. The presence of this mutation is a marker of adverse outcome.
Specifically, Quizartinib selectively inhibits class III receptor tyrosine kinases, including FMS-related tyrosine kinase 3 (FLT3/STK1), colony-stimulating factor 1 receptor (CSF1R/FMS), stem cell factor receptor (SCFR/KIT), and platelet derived growth factor receptors (PDGFRs).Mutations cause constitutive action of Flt3 leading to resulting in inhibition of ligand-independent leukemic cell proliferation and apoptosis
It had good results in a phase II clinical trial for refractory AML – particularly in patients who went on to have a stem cell transplant.[2]
- Chao, Qi; Sprankle, Kelly G.; Grotzfeld, Robert M.; Lai, Andiliy G.; Carter, Todd A.; Velasco, Anne Marie; Gunawardane, Ruwanthi N.; Cramer, Merryl D.; Gardner, Michael F.; James, Joyce; Zarrinkar, Patrick P.; Patel, Hitesh K.; Bhagwat, Shripad S. (2009). “Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N’-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor”. Journal of Medicinal Chemistry 52 (23): 7808–7816.
- Drug Tames Refractory AML. ASH Dec 2012
Drug Delivery With A Bang, Nanoscience: Chain-shattering polymeric therapeutics could release medicines on demand

Process for the preparation of oseltamivir and methyl 3-epi-shikimate,Council Of Scientific & Industrial Research, INDIA
oseltamivir
Process for the preparation of oseltamivir and methyl 3-epi-shikimate, for Influenza virus infection
WO 2013061340
BY
Rawat, Varun; Dey, Soumen; Arumugam, Sudalai
The present invention discloses high yielding enantioselective process for synthesis of Oseltamivir from readily available starting material, cis-1,4-butene diol.The process features incorporation of chirality using sharpless asymmetric epoxidation(AE) and diastereoselective Barbier allylation and construction of cyclohexene carboxylic acid ester core through a ring closing metathesis (RCM) reaction. Further also disclosed herein is synthesis of (-)-methyl 3-epi-shikimate.
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....











